Stay updated with breaking news from Lung Division. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
THOUSAND OAKS (dpa-AFX) - Amgen (AMGN) and AstraZeneca Thursday said results from the Phase 3 study of tezepelumab in severe asthma patients, dubbed Navigator, have been published in the New England
New Medication Reduces Asthma Exacerbations and Improves Lung Function in Patients with Severe, Uncontrolled Asthma Share Article Results from the phase 3 NAVIGATOR study was presented during the 2021 AAAAI Virtual Annual Meeting. "Tezepelumab has the potential to transform treatment for a broad population of patients with severe asthma irrespective of their type of inflammation, including those with and without an eosinophilic phenotype.” MILWAUKEE (PRWEB) February 26, 2021 Tezepelumab, a human monoclonal antibody, was found ...
AstraZeneca, Amgen Report Positive Tezepelumab Study Results Fri, 26th Feb 2021 14:27 (Alliance News) - AstraZeneca PLC and Amgen Inc on Friday said positive full results from the Navigator phase III trial of tezepelumab showed a reduction in the annualised asthma exacerbation rate in severe, uncontrolled asthma patients. Tezepelumab blocks the action of thymic stromal lymphopoietin, an epithelial cytokine that plays a key role across the spectrum of asthma inflammation. The Cambridge, England-based biopharmaceutical company also said tezepelumab demonstrated statistically significant improv...